%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
86 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-04-30T07:55:27Z
2024-03-28T13:19:17-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:19:17-07:00
application/pdf
Heather
2004-14.may.suppl 71
uuid:b330f8ee-1dd1-11b2-0a00-da09275d6100
uuid:b330f8f4-1dd1-11b2-0a00-aa0000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
100 0 obj
[104 0 R]
endobj
101 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.07201 Tw 10 0 0 10 54 713.1616 Tm
(incidence of infection to be similar in patients treated with)Tj
0.0148 Tw 0 -1.2 TD
(leflunomide and with other DMARD \(with the exception of)Tj
0.2746 Tw T*
(biological agents\). Respiratory infections were the most)Tj
0.0063 Tw T*
(commonly reported. Over two-thirds reported the infections)Tj
-0.03619 Tw T*
(as mild, and 95% stated that they resolve during leflunomide)Tj
0.1524 Tw T*
(treatment. Nearly one-half \(47%\) the Expert Panel would)Tj
-0.0202 Tw T*
(maintain the dose, although 37% would stop leflunomide, in)Tj
0.02499 Tw T*
(patients with infections. )Tj
/T1_2 1 Tf
-0.0101 Tc 0 Tw 0 -1.44 TD
(Cytopenia)Tj
/T1_1 1 Tf
0.01401 Tw [-0.3 (. Current labelling for leflunomide in the European)]TJ
0.03329 Tw 0 -1.2 TD
[(Union requires a complete blood cell count, including dif)17.9 (fer-)]TJ
0.039 Tw T*
(ential white blood cell count and platelets, before the start of)Tj
-0.02409 Tw T*
(leflunomide treatment, every 2 weeks for the first 6 months of)Tj
0.02499 Tw T*
[(treatment, and every 8 weeks subsequently)65 (.)]TJ
-0.00011 Tc 0.175 Tw 1.2 -1.2 Td
(The entire Expert Panel would stop leflunomide treat-)Tj
0.1017 Tw -1.2 -1.2 Td
[(ment if the patient\325)54.8 (s neutrophil count decreased to < 1000)]TJ
-0.0004 Tc 0 Tw T*
(mm)Tj
0 Tc 6.5 0 0 6.5 69.5566 534.0616 Tm
(3)Tj
-0.00011 Tc 0.06081 Tw 10 0 0 10 72.8066 530.7616 Tm
[(. )54.9 (All the expert participants would stop leflunomide in)]TJ
0.0108 Tc 0.36411 Tw -1.8807 -1.2 Td
(these patients; 64% would also do so in those with)Tj
-0.00011 Tc 0.2291 Tw T*
(neutrophil counts of 1000\3201500/mm)Tj
0 Tc 0 Tw 6.5 0 0 6.5 207.2432 510.0616 Tm
(3)Tj
-0.00011 Tc 0.2291 Tw 10 0 0 10 210.4931 506.7616 Tm
(, although a further)Tj
0.35159 Tw -15.6493 -1.2 Td
[(29% would reduce the dose instead. )54.7 (All reported that)]TJ
-0.0295 Tw T*
(neutropenia is reversible, either during therapy or after treat-)Tj
0.22771 Tw T*
(ment is stopped. Eosinophilia, anemia, and lymphopenia)Tj
0.02499 Tw T*
(were not a concern according to the experts.)Tj
-0.0249 Tw 1.2 -1.2 Td
(There is a need to monitor blood counts in patients taking)Tj
0.09669 Tw -1.2 -1.2 Td
(leflunomide, according to the summary of product charac-)Tj
0.1904 Tw T*
[(teristics; however)39.7 (, it should be noted that all the experts)]TJ
0.19521 Tw T*
(stated that the frequency of this monitoring is similar to)Tj
0.0079 Tc 0.367 Tw T*
(other DMARD such as sulfasalazine or methotrexate.)Tj
-0.00011 Tc 0.0945 Tw T*
[(Should cytopenia occur)39.7 (, a search for confounding medica-)]TJ
0.0322 Tw T*
(tions or other causes should be undertaken. Should lefluno-)Tj
0.1266 Tw T*
(mide be associated with significant cytopenia, appropriate)Tj
0.15199 Tw T*
(measures should be taken; for example, stopping lefluno-)Tj
0.02499 Tw T*
[(mide and, if necessary)64.8 (, initiating a washout procedure.)]TJ
/T1_2 1 Tf
0 Tc -0.0303 Tw 0 -1.44 TD
[(W)92 (ashout pr)36.8 (ocedur)36.9 (e)]TJ
/T1_1 1 Tf
-0.00011 Tc 7.6631 0 Td
(. Indications of a severe reaction \(inflam-)Tj
0.2076 Tw -7.6631 -1.2 Td
[(mation of the buccal or genital mucosa, fever)39.7 (, extensive)]TJ
-0.0304 Tw 0 -1.2 TD
(body rash, including bullous reactions or other signs sugges-)Tj
0.1189 Tw T*
(tive of Stevens-Johnson or similar syndromes\) or signs of)Tj
0.0898 Tw T*
(anaphylaxis \(e.g., angioedema\) or severe, poorly tolerated,)Tj
0.0065 Tw T*
(alopecia, warrant immediate withdrawal of leflunomide and)Tj
0.05659 Tw T*
(initiation of the washout procedure. Following cessation of)Tj
0.04449 Tw T*
[(leflunomide, an 1)36.7 (1-day washout period commences, during)]TJ
0.3662 Tw T*
[(which cholestyramine \(8 g tid\) is administered. )54.8 (Alter-)]TJ
0.0546 Tw T*
[(natively)64.8 (, activated charcoal \(50 g qds\) is administered over)]TJ
0.209 Tw T*
(the same period. It should be noted that the duration of)Tj
0.0011 Tw T*
(washout may be modified depending on clinical and labora-)Tj
0.02499 Tw T*
(tory variables.)Tj
0.07471 Tw 1.2 -1.2 Td
(When leflunomide, administered at a daily maintenance)Tj
-0.02721 Tw -1.2 -1.2 Td
(dose of 20 mg, is withdrawn, it is estimated that levels of the)Tj
-0.00211 Tw T*
(active metabolite will remain above the limit of detection of)Tj
0.16141 Tw T*
(0.02 mg/l in approximately one-half of all patients for at)Tj
0.0184 Tw 26.4 58.08 Td
(least 22 weeks, although most will have undetectable levels)Tj
0.03571 Tw T*
(1 year after stopping treatment)Tj
0 Tc 0 Tw 6.5 0 0 6.5 442.1467 704.4616 Tm
(10)Tj
-0.00011 Tc 0.03571 Tw 10 0 0 10 448.6467 701.1616 Tm
(. Cholestyramine can facil-)Tj
0.08099 Tw -13.0647 -1.2 Td
[(itate the rapid elimination of leflunomide. One day\325)54.8 (s treat-)]TJ
0.2816 Tw T*
(ment with cholestyramine \(4 g tid\) has been shown to)Tj
-0.03349 Tw T*
(shorten the half-life of leflunomide dramatically so that 90%)Tj
0.02499 Tw T*
(of patients have undetectable levels after 3 weeks)Tj
0 Tc 0 Tw 6.5 0 0 6.5 517.7018 656.4615 Tm
(10)Tj
10 0 0 10 524.2017 653.1616 Tm
(.)Tj
/T1_3 1 Tf
-0.00011 Tc -20.6202 -2.4 Td
(CONCLUSION)Tj
/T1_1 1 Tf
0.2263 Tw T*
(Most of the Expert Panel consider adverse events to be)Tj
0.3743 Tw T*
(manageable when the practical recommendations listed)Tj
0.1521 Tw T*
[(above are followed. )54.8 (At the same time, patients should be)]TJ
0.2162 Tw T*
(supported and involved in the management of their side)Tj
0.2812 Tw T*
[(ef)17.7 (fects; this will require support from nurses and other)]TJ
0.02499 Tw T*
(healthcare professionals.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 325 523.1616 Tm
[(1.)-875.1 (Strand )17.7 (V)128.9 (, Cohen S, Schif)17.7 (f M, et al. )17.7 (T)35 (reatment of active rheumatoid)]TJ
1.675 -1.25 Td
(arthritis with leflunomide compared with placebo and methotrexate.)Tj
0 -1.25 TD
[(Leflunomide Rheumatoid )54.8 (Arthritis Investigators Group. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 1999;159:2542-50.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Schif)17.7 (f MH, Strand )17.7 (V)128.9 (, Oed C, Loew-Friedrich I. Leflunomide: )]TJ
1.675 -1.25 Td
[(ef)17.7 (ficacy and safety in clinical trials for the treatment of rheumatoid)]TJ
T*
[(arthritis. Drugs )17.7 (T)69.9 (oday Barc 2000;36:383-94.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Arava summary of product characteristics. [Internet]. )54.8 (Accessed)]TJ
0 Tc 1.675 -1.25 Td
[(February 10, 2004. )54.8 (A)74.1 (vailable from: )]TJ
-0.00011 Tc 0 Tw T*
[(http://www)64.8 (.aventis-us.com/PIs/arava_TXT)73.9 (.html.)]TJ
-0.0298 Tw -1.675 -1.25 Td
[(4.)-875.1 (Food )-54.9 (and )-54.9 (Drug Administration Arthritis Advisory )-54.8 (Committee.)]TJ
0.02499 Tw 1.675 -1.25 Td
[(Briefing information. )54.8 (Arava \(leflunomide\) 2003. [Internet].)]TJ
T*
[(Accessed February 10, 2004. )54.8 (A)74 (vailable from:)]TJ
0 Tw T*
[(http://www)64.8 (.fda.gov/ohrms/dockets/ac/03/briefing/3930b2.htm.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Cannon G, Schif)17.7 (f M, Strand )17.7 (V)128.9 (,)-0.1 ( Holden )17.7 (W)91.8 (. Hepatic adverse events)]TJ
1.675 -1.25 Td
(and other toxicity during treatment with leflunomide, methotrexate,)Tj
T*
(other disease modifying antirheumatic drugs \(DMARDs\), and)Tj
T*
(combination DMARD therapy: Comparison to NSAID alone and)Tj
T*
[(adjustment for comorbidities category [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(2002;46 Suppl:S357.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Emery P)110.7 (,)-0.1 ( Cannon G, Holden )17.7 (W)91.9 (, Strand )17.7 (V)128.9 (, Schif)17.7 (f M. Results from a)]TJ
1.675 -1.25 Td
(cohort of over 40,000 rheumatoid arthritis patients: adverse event)Tj
T*
(profiles of leflunomide, methotrexate and other disease-modifying)Tj
T*
[(antirheumatic drugs [abstract]. )54.8 (Ann Rheum Dis 2002;61 Suppl)]TJ
0 Tc 0 Tw T*
(1:42. )Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Smolen JS. Practical management of rheumatoid arthritis patients)]TJ
1.675 -1.25 Td
(treated with leflunomide. Introduction. J Rheumatol 2004;31 Suppl)Tj
0 Tw T*
(71:1-12.)Tj
0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Mladenovic )17.7 (V)128.9 (, Domljan Z, Rozman B, et al. Safety and )]TJ
1.675 -1.25 Td
[(ef)17.7 (fectiveness of leflunomide in the treatment of patients with active)]TJ
T*
(rheumatoid arthritis. Results of a randomized, placebo-controlled,)Tj
T*
[(phase II study)64.8 (. )54.8 (Arthritis Rheum 1995;38:1595-603.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Aletaha D, Stamm )17.7 (T)74 (, Kapral )17.7 (T)74 (, et al. Survival and ef)17.7 (fectiveness of)]TJ
1.675 -1.25 Td
(leflunomide compared with methotrexate and sulfasalazine in)Tj
T*
[(rheumatoid arthritis: a matched observational study)64.8 (. )54.8 (Ann Rheum)]TJ
0 Tc T*
(Dis 2003;62:944-51.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Strand )17.7 (V)128.9 (, Sharp JT)73.9 (. Radiographic data from recent randomized)]TJ
2.175 -1.25 Td
(controlled trials in rheumatoid arthritis: what have we learned?)Tj
T*
(Arthritis Rheum 2003;48:21-34.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2004, V)110.7 (olume 31, Supplement 71)]TJ
0 Tc 0 Tw -37.5268 -0.0313 Td
(24)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>stream
8;Z\6fl@0<%-.A;:qtJI"R9RCU3n
Ln-O!WaAlY2$#enK(iqp9VaSaX%riJ0Y$-Hr0d^!f$O//)%38p?=>7@*gCt9dg>rS
o%Yh_Kp[Z8^$!.,!A%S@_eK\6HZDJI9QLG?ddt`CeLq8=a,O*b&e\nf*XUA#55M@4
MAOeVatj8qi%SR/nAuk>C`';75jb6:('DafIWO]All1BsiW&a6G,oU?YHbjUWEV)6
CW*F1jbau#?$J,V]E$392f'NCCjNLfk[1XN\Gup/CS@eEC<]
'H)ogYH!Yml(fKL%E@mhU)Z!#SXK3qmdf=_MpOf7C=J;]PP$0ccX+/Q(dJ1Wns#0fC
&!"R4a=eI;_Ui5DmutFBr<.QR!-FmJWW~>
endstream
endobj
25 0 obj
[/Indexed/DeviceRGB 255 24 0 R]
endobj
24 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
77 0 obj
<>
endobj
47 0 obj
<>
endobj
45 0 obj
<>
endobj
49 0 obj
<>
endobj
68 0 obj
<>
endobj
91 0 obj
<>
endobj
50 0 obj
<>
endobj
58 0 obj
<>stream
H\TkPW/lDbL\q3
`yDLELL#AGag(y(3Q<%>+Z ꢸVR4fu5VNwkv:uswpCd2CVKҚ|BWPd0e Rlxv QX8b" wO~+/<'h4j4~&9ݖf-_8G~vdijkM$z!.3&sju^"QZ.zu&u:&ruΐnԪ?S?I:)[.^鴦ѷR$MC( b*ALs'BsHb; JXE2" )bwˉc[zY͘1bjǻ'_"5 ʇP<6y ;W0!`"}lb,dBW穓]絧7n7-wɯy:-|ms.us
͛~&;#)(Sn$αSQq4`bcٖ^*'Nů`}l]PwsN9AIJCg8
>0sACvl7<%NӰ#C&|D\[3{=_Bh GAipj 7*Eik=qB fC8K.T/({Tu{~vߐSyF%&o(!&" fdS8ok`\Joci3'3O՚>=er]$<\UOS